Insider · CIK 0001553352

Lewicki John A.

Reports to the SEC for 2 companies · LONDON, X0

sec.gov

Transactions

Companies

Filings

CIK

0001553352

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-01	MREOMereo BioPharma Group plc · Share Options (Right to buy)A Award	Chief Scientific Officer	AAward	+140K sh	—	—	139,913
2026-02-01	MREOMereo BioPharma Group plc · Share Options (Right to buy)A Award	Chief Scientific Officer	AAward	+46.6K sh	—	—	46,637
2026-02-01	MREOMereo BioPharma Group plc · Share Options (Right to buy)A Award	Chief Scientific Officer	AAward	+145K sh	—	—	145,000
2025-01-25	MREOMereo BioPharma Group plc · Share Options (Right to buy)A Award	Chief Scientific Officer	AAward	+116K sh	—	—	116,000
2024-09-13	MREOMereo BioPharma Group plcS Sale	Chief Scientific Officer	SSale	−10.9K sh	$4.22	−$46.2K	78,630
2024-09-12	MREOMereo BioPharma Group plcS Sale	Chief Scientific Officer	SSale	−5,212 sh	$4.47	−$23.3K	89,567
2024-09-11	MREOMereo BioPharma Group plcM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+46K sh	—	—	94,779
2024-09-11	MREOMereo BioPharma Group plc · Performance Based Restricted Stock UnitM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−46K sh	—	—	0
2024-06-26	MREOMereo BioPharma Group plcS Sale	Chief Scientific Officer	SSale	−16.8K sh	$3.39	−$57K	48,779
2024-06-25	MREOMereo BioPharma Group plcS Sale	Chief Scientific Officer	SSale	−7,416 sh	$3.69	−$27.4K	65,587
2024-06-21	MREOMereo BioPharma Group plcM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+69K sh	—	—	73,003
2024-06-21	MREOMereo BioPharma Group plc · Performance Based Restricted Stock UnitM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+69K sh	—	—	46,000
2024-01-25	MREOMereo BioPharma Group plc · Share Options (Right to buy)A Award	Chief Scientific Officer	AAward	+137K sh	—	—	137,000
2019-04-23	OncoMed Pharmaceuticals IncU Disposition from Tender	Director, President and CEO	UDisposition from Tender	−143K sh	—	—	0
2018-10-10	OncoMed Pharmaceuticals IncS Sale	Director, President and CEO	SSale	−1,156 sh	$2.01	−$2,323.56	55,966
2018-10-09	OncoMed Pharmaceuticals IncS Sale	Director, President and CEO	SSale	−2,296 sh	$2.13	−$4,887.954	57,122
2018-08-06	OncoMed Pharmaceuticals IncG Gift	Director, President and CEO	GGift	−11.8K sh	—	—	44,173
2018-08-06	OncoMed Pharmaceuticals IncG Gift	Director, President and CEO	GGift	+11.8K sh	—	—	111,181
2018-04-24	OncoMed Pharmaceuticals IncS Sale	Director, President and CEO	SSale	−4,557 sh	$2.68	−$12.2K	55,418
2018-03-16	OncoMed Pharmaceuticals IncStock Option (Right to Buy)A Award	Director, President and CEO	AAward	+125K sh	—	—	125,000
2018-02-21	OncoMed Pharmaceuticals IncStock Option (Right to Buy)A Award	Director, President and CEO	AAward	+125K sh	—	—	125,000
2017-10-10	OncoMed Pharmaceuticals IncS Sale	Director, President and CEO	SSale	−46 sh	$4.26	−$195.978	71,614
2017-10-10	OncoMed Pharmaceuticals IncS Sale	Director, President and CEO	SSale	−1,202 sh	$4.24	−$5,098.644	70,412
2017-10-07	OncoMed Pharmaceuticals IncA Award	Director, President and CEO	AAward	+25K sh	—	—	71,660
2017-10-07	OncoMed Pharmaceuticals IncStock Option (Right to Buy)A Award	Director, President and CEO	AAward	+50K sh	—	—	50,000
2017-05-10	OncoMed Pharmaceuticals IncG Gift	Director, President and CEO	GGift	−10.4K sh	—	—	59,975
2017-05-10	OncoMed Pharmaceuticals IncG Gift	Director, President and CEO	GGift	+10.4K sh	—	—	99,388
2017-04-23	OncoMed Pharmaceuticals IncA Award	Director, President and CEO	AAward	+22.5K sh	—	—	45,437
2017-04-23	OncoMed Pharmaceuticals IncStock Option (Right to Buy)A Award	Director, President and CEO	AAward	+67.5K sh	—	—	67,500
2017-04-04	OncoMed Pharmaceuticals IncS Sale	Director, President and CEO	SSale	−43 sh	$8.87	−$381.285	28,648
2017-04-04	OncoMed Pharmaceuticals IncS Sale	Director, President and CEO	SSale	−5,711 sh	$9.06	−$51.7K	22,937
2017-01-03	OncoMed Pharmaceuticals IncM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+9,175 sh	$1.43	+$13.1K	40,811
2017-01-03	OncoMed Pharmaceuticals IncS Sale	Director, President and CEO	SSale	−9,175 sh	$7.63	−$70K	31,636
2017-01-03	OncoMed Pharmaceuticals IncStock Option (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−9,175 sh	—	—	0
2017-01-03	OncoMed Pharmaceuticals IncStock Option (Right to Buy)A Award	Director, President and CEO	AAward	+65K sh	—	—	65,000
2016-10-09	OncoMed Pharmaceuticals IncA Award	Director, President and CEO	AAward	+12.5K sh	—	—	31,636
2016-01-07	OncoMed Pharmaceuticals IncS Sale	Director, President and CEO	SSale	−1 sh	$21.33	−$21.33	17,838
2016-01-06	OncoMed Pharmaceuticals IncS Sale	Director, President and CEO	SSale	−2,092 sh	$22.30	−$46.7K	17,908
2016-01-06	OncoMed Pharmaceuticals IncS Sale	Director, President and CEO	SSale	−69 sh	$21.56	−$1,487.813	17,839
2015-12-27	OncoMed Pharmaceuticals IncStock Option (Right to Buy)A Award	Director, President and CEO	AAward	+70K sh	—	—	70,000
2015-06-16	OncoMed Pharmaceuticals IncM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+5,602 sh	$1.43	+$8,010.86	25,602
2015-06-16	OncoMed Pharmaceuticals IncM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+2,898 sh	$3.42	+$9,911.16	28,500
2015-06-16	OncoMed Pharmaceuticals IncS Sale	Director, President and CEO	SSale	−8,500 sh	$25.22	−$214K	20,000
2015-06-16	OncoMed Pharmaceuticals IncStock Option (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−5,602 sh	—	—	9,175
2015-06-16	OncoMed Pharmaceuticals IncStock Option (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−2,898 sh	—	—	134,423
2015-06-15	OncoMed Pharmaceuticals IncM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+8,500 sh	$1.43	+$12.2K	28,500
2015-06-15	OncoMed Pharmaceuticals IncS Sale	Director, President and CEO	SSale	−8,500 sh	$24.92	−$212K	20,000
2015-06-15	OncoMed Pharmaceuticals IncStock Option (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−8,500 sh	—	—	14,777
2015-04-02	OncoMed Pharmaceuticals IncM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+8,500 sh	$1.43	+$12.2K	29,785
2015-04-02	OncoMed Pharmaceuticals IncS Sale	Director, President and CEO	SSale	−6,940 sh	$25.29	−$176K	22,845

Recent filings

Accepted (ET)
Feb 24
Lewicki John A.0001193125-26-033754
SEC(opens sec.gov)
Jan 284
Lewicki John A.0000950170-25-009794
SEC(opens sec.gov)
Sep 164
Lewicki John A.0000950170-24-106974
SEC(opens sec.gov)
Sep 134
Lewicki John A.0000950170-24-106418
SEC(opens sec.gov)
Jun 274
Lewicki John A.0000950170-24-078468
SEC(opens sec.gov)
Jun 254
Lewicki John A.0000950170-24-077487
SEC(opens sec.gov)
Jan 264
Lewicki John A.0000950170-24-007936
SEC(opens sec.gov)
Apr 234
Lewicki John A.0000899243-19-010987
SEC(opens sec.gov)
Feb 135
Lewicki John A.0001567619-19-003877
SEC(opens sec.gov)
Oct 114
Lewicki John A.0001567619-18-004054
SEC(opens sec.gov)
Oct 104
Lewicki John A.0001567619-18-003956
SEC(opens sec.gov)
Apr 264
Lewicki John A.0001140361-18-019833
SEC(opens sec.gov)
Mar 194
Lewicki John A.0001140361-18-014120
SEC(opens sec.gov)

Companies

Address

C/O MEREO BIOPHARMA GROUP PLC 4TH FLOOR, ONE CAVENDISH PLACE

LONDON, X0, W1G 0QF